Errant Gene Therapeutics, LLC
https://errantgene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Errant Gene Therapeutics, LLC
US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns
San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA to delay approval of bluebird’s BLA until resolution of a patent case and a ‘careful investigation’ of Zynteglo’s risks.
Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
UK Firms Big And Small Benefit From Biotech Bubble
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice